Canada:
Supreme Court Of Canada Denies Leave To Hear Section 8 Case
15 June 2012
Beeser Ramamoorthy LLP
To print this article, all you need is to be registered or login on Mondaq.com.
On June 14, 2012, the Supreme Court of Canada ("SCC")
denied leave to hear an appeal involving section 8 of the Patented
Medicines (Notice of Compliance) Regulations. The case involves
Merck and Apotex regarding the drug lovastatin. The SCC's
summary of the leave case can be found
here.
Consistent with its practice, the SCC did not provide reasons
for the denial of the leave application.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Intellectual Property from Canada
Copyright: 2023 Year In Review
Cassels
Join the Cassels Copyright team as we look back at some of the most notable Canadian copyright law decisions, legislative amendments, and other developments from 2023.
Intellectual Property 101
Blake, Cassels & Graydon LLP
For many startups and scaleups, intellectual property (IP) is crucial to the company's competitive advantage and, therefore, its overall success and value.